FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307029312> ?p ?o ?g. }

• W4307029312 abstract "Abstract The aim of the study was to assess the predictive value of interim FDG-PET/CT (iPET) in patients with Hodgkin’s lymphoma (HL) treated with Adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy. A total of 245 consecutive patients with de novo HL between 12/2013 and 12/2017 were evaluated retrospectively. All patients were treated with upfront ABVD, performed PET/CT scans at baseline, after 2 cycles (interim PET, iPET2) or 4 cycles (iPET4) and at the end of therapy, and followed up for at least 6 months after therapy. The response status on iPET was defined according to the standard five-point Deauville scores (DS) as follows: complete metabolic response (CMR, DS 1–3) and non-complete metabolic response (nCMR) (DS 4 and 5). End-of-treatment (EoT) response was assessed by FDG-PET/CT and if needed biopsy confirmation of PET-positive findings. The association between iPET and EoT response was investigated using logistic regression analysis. Survival analysis was performed using the Cox regression hazard model and Kaplan–Meier methods. Sixty-nine patients underwent iPET-2 and 176 iPET-4. No association was found between the timing of iPET and iPET response status ( P -value = 0.71). Two hundred and one patients (82%) had iPET-CMR and 44 (18%) iPET -nCMR. iPET was strongly associated with EoT response status: 194/201 (96 .5%) of iPET-CMR had a complete response at the EoT while only 21/44 (47.7%) of patients with iPET-nCMR presented a complete response at EoT ( P -value < 0.0001). The median follow-up was 32 months (range 6–81). Patients with iPET-CMR presented a better outcome with 91% 3 y event-free-survival (EFS) and 95% 3 y overall survival (OS) than those with iPET-nCMR (41 and 86%, respectively, P -value < 0.0001). In multivariable analyses, iPET retained an independent prognostic factor of EFS and OS ( P -value < 0.0001 and P -value = 0.002, respectively). iPET is highly predictive of outcome of HL patients treated with ABVD and allows to tailor therapy to the individual patient." @default.
• W4307029312 created "2022-10-22" @default.
• W4307029312 creator A5020839601 @default.
• W4307029312 creator A5030382047 @default.
• W4307029312 creator A5044630159 @default.
• W4307029312 creator A5045921833 @default.
• W4307029312 creator A5057748098 @default.
• W4307029312 creator A5060088290 @default.
• W4307029312 creator A5060930126 @default.
• W4307029312 creator A5065042690 @default.
• W4307029312 creator A5066048708 @default.
• W4307029312 creator A5070338918 @default.
• W4307029312 creator A5079665748 @default.
• W4307029312 creator A5085020135 @default.
• W4307029312 date "2022-10-21" @default.
• W4307029312 modified "2023-10-14" @default.
• W4307029312 title "Interim FDG-PET/CT for therapy monitoring and prognostication in Hodgkin’s Lymphoma" @default.
• W4307029312 cites W2010746974 @default.
• W4307029312 cites W2012980713 @default.
• W4307029312 cites W2028099607 @default.
• W4307029312 cites W2039888190 @default.
• W4307029312 cites W2101873015 @default.
• W4307029312 cites W2119147717 @default.
• W4307029312 cites W2119843363 @default.
• W4307029312 cites W2124587380 @default.
• W4307029312 cites W2126297385 @default.
• W4307029312 cites W2131900456 @default.
• W4307029312 cites W2137965731 @default.
• W4307029312 cites W2162340856 @default.
• W4307029312 cites W2274888609 @default.
• W4307029312 cites W2469052042 @default.
• W4307029312 cites W2598700764 @default.
• W4307029312 cites W2949084717 @default.
• W4307029312 cites W2994736370 @default.
• W4307029312 cites W3033765098 @default.
• W4307029312 cites W3180573537 @default.
• W4307029312 cites W3186567564 @default.
• W4307029312 cites W4205882386 @default.
• W4307029312 doi "https://doi.org/10.1038/s41598-022-22032-3" @default.
• W4307029312 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36271128" @default.
• W4307029312 hasPublicationYear "2022" @default.
• W4307029312 type Work @default.
• W4307029312 citedByCount "3" @default.
• W4307029312 countsByYear W43070293122023 @default.
• W4307029312 crossrefType "journal-article" @default.
• W4307029312 hasAuthorship W4307029312A5020839601 @default.
• W4307029312 hasAuthorship W4307029312A5030382047 @default.
• W4307029312 hasAuthorship W4307029312A5044630159 @default.
• W4307029312 hasAuthorship W4307029312A5045921833 @default.
• W4307029312 hasAuthorship W4307029312A5057748098 @default.
• W4307029312 hasAuthorship W4307029312A5060088290 @default.
• W4307029312 hasAuthorship W4307029312A5060930126 @default.
• W4307029312 hasAuthorship W4307029312A5065042690 @default.
• W4307029312 hasAuthorship W4307029312A5066048708 @default.
• W4307029312 hasAuthorship W4307029312A5070338918 @default.
• W4307029312 hasAuthorship W4307029312A5079665748 @default.
• W4307029312 hasAuthorship W4307029312A5085020135 @default.
• W4307029312 hasBestOaLocation W43070293121 @default.
• W4307029312 hasConcept C126322002 @default.
• W4307029312 hasConcept C143998085 @default.
• W4307029312 hasConcept C207103383 @default.
• W4307029312 hasConcept C2776305933 @default.
• W4307029312 hasConcept C2776694085 @default.
• W4307029312 hasConcept C2776755627 @default.
• W4307029312 hasConcept C2777132456 @default.
• W4307029312 hasConcept C2779338263 @default.
• W4307029312 hasConcept C2779429289 @default.
• W4307029312 hasConcept C2780964509 @default.
• W4307029312 hasConcept C2989005 @default.
• W4307029312 hasConcept C2992779791 @default.
• W4307029312 hasConcept C44249647 @default.
• W4307029312 hasConcept C50382708 @default.
• W4307029312 hasConcept C71924100 @default.
• W4307029312 hasConceptScore W4307029312C126322002 @default.
• W4307029312 hasConceptScore W4307029312C143998085 @default.
• W4307029312 hasConceptScore W4307029312C207103383 @default.
• W4307029312 hasConceptScore W4307029312C2776305933 @default.
• W4307029312 hasConceptScore W4307029312C2776694085 @default.
• W4307029312 hasConceptScore W4307029312C2776755627 @default.
• W4307029312 hasConceptScore W4307029312C2777132456 @default.
• W4307029312 hasConceptScore W4307029312C2779338263 @default.
• W4307029312 hasConceptScore W4307029312C2779429289 @default.
• W4307029312 hasConceptScore W4307029312C2780964509 @default.
• W4307029312 hasConceptScore W4307029312C2989005 @default.
• W4307029312 hasConceptScore W4307029312C2992779791 @default.
• W4307029312 hasConceptScore W4307029312C44249647 @default.
• W4307029312 hasConceptScore W4307029312C50382708 @default.
• W4307029312 hasConceptScore W4307029312C71924100 @default.
• W4307029312 hasIssue "1" @default.
• W4307029312 hasLocation W43070293121 @default.
• W4307029312 hasLocation W43070293122 @default.
• W4307029312 hasLocation W43070293123 @default.
• W4307029312 hasLocation W43070293124 @default.
• W4307029312 hasOpenAccess W4307029312 @default.
• W4307029312 hasPrimaryLocation W43070293121 @default.
• W4307029312 hasRelatedWork W16457442 @default.
• W4307029312 hasRelatedWork W1996513777 @default.
• W4307029312 hasRelatedWork W2114589251 @default.
• W4307029312 hasRelatedWork W2291534125 @default.
• W4307029312 hasRelatedWork W2323121657 @default.

• next